Modified-Release Granules for High-Dose GHB Prodrug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oral pharmaceutical compositions face challenges in administering high doses of active ingredients with minimal excipients, requiring improved palatability and controlled release profiles, particularly for treating conditions like narcolepsy and excessive daytime sleepiness.
Innovation Solution
Development of modified release pharmaceutical granulations with a core containing 4-((L-valyl)oxy)butanoic acid, coated with a matrix polymer and antistatic agent, achieving a particle size distribution of 200-400 μm and a coating composition of 6-14% solids, 0-20% water, and 70-95% ethanol, to provide controlled release of γ-hydroxybutyrate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high dose of active ingredient is administered to minimize amount of oral pharmaceutical composition, then therapeutic efficacy is improved, but palatability deteriorates
Solution Approach 1:
The pharmaceutical composition is divided into multiple granules with different release profiles (immediate release and modified release granules), allowing the active ingredient to be distributed in a way that maintains high dosage while improving sensory properties through the matrix structure and coating
Solution Approach 2:
The granules utilize composite material structures including matrix polymers (ethyl cellulose, hydroxypropyl cellulose), coating materials, and antistatic agents combined in specific ratios to create a formulation that achieves both high active ingredient content and improved palatability through controlled release mechanisms
2Duration of action of moving object
If modified release coating is applied to provide controlled release profile, then duration of action is improved, but device complexity increases
Solution Approach 1:
The release profile is controlled by changing the parameters of the coating layer including thickness (1-10 μm), composition ratios (ethyl cellulose:hydroxypropyl cellulose), and porosity, allowing adjustment of release duration without fundamentally changing the granule structure
Solution Approach 2:
The modified release coating utilizes porous matrix materials that allow controlled diffusion of the active ingredient through the coating layer, achieving extended release duration through the inherent porosity and swelling properties of the polymer matrix rather than complex mechanical structures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The granulations enable effective treatment of narcolepsy and excessive daytime sleepiness by ensuring high active ingredient content, improved palatability, and controlled release, enhancing therapeutic efficacy and patient compliance.
Implementation Method 1
a modified release coating that provides a desired release profile in the gastrointestinal tract
Implementation Method 2
a modified release coating comprising: from 50 wt % to 85 wt % of a matrix polymer
Implementation Method 3
from 10 wt % to 20 wt % an antistatic agent
Data Source
AI summary
Pharmaceutical granulations having a functional coating surrounding a core containing 4-((L-valyl)oxy)butanoic acid are disclosed. The functional coatings provide for immediate release or modified release of 4-((L-valyl)oxy)butanoic acid. The pharmaceutical granulations can be used in oral pharmaceutical compositions.